Palisade Bio (PALI) director purchase of 5,000 shares disclosed

Rhea-AI Filing Summary

Palisade Bio, Inc. director Donald Allen Williams reported buying 5,000 shares of common stock on January 9, 2026 at a price of $1.88 per share. After this open-market purchase, he directly owns 5,728 common shares and has an additional 3,000 shares reported as indirectly owned through the reporting person's defined benefit plan.

Insider Trade Summary

Net Buyer: 5,000 shares ($9,400)

Net Buy 2 txns

Insider Williams Donald Allen

Role Director

Bought 5,000 shs ($9K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	5,000	$1.88	$9K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 5,728 shares (Direct); Common Stock — 3,000 shares (Indirect, By Reporting Person's Defined Benefit Plan)

Footnotes (1)

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Williams Donald Allen

(Last) (First) (Middle)

1902 WRIGHT PLACE, SUITE 200

(Street)

CARLSBAD CA 92008

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PALISADE BIO, INC. [ PALI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/09/2026		P		5,000	A	$1.88	5,728	D
Common Stock								3,000	I	By Reporting Person's Defined Benefit Plan

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Ryker Willie, Attorney-in-Fact	01/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Palisade Bio (PALI) report on this Form 4?

The filing shows that director Donald Allen Williams purchased 5,000 shares of Palisade Bio common stock at $1.88 per share on January 9, 2026.

What is Donald Allen Williams' role at Palisade Bio (PALI)?

Donald Allen Williams is reported as a director of Palisade Bio, Inc. and is not listed as an officer or 10% owner in this filing.

How many Palisade Bio (PALI) shares does the director own after this transaction?

Following the transaction, Donald Allen Williams directly owns 5,728 common shares and indirectly reports ownership of 3,000 shares through the reporting person's defined benefit plan.

Was this Palisade Bio (PALI) insider trade a purchase or a sale?

The Form 4 reports a purchase transaction, coded "P", for 5,000 shares of Palisade Bio common stock at $1.88 per share.

How are the indirect Palisade Bio (PALI) shares held for the reporting person?

The filing lists 3,000 common shares as indirectly owned by the reporting person through a defined benefit plan, described as "By Reporting Person's Defined Benefit Plan."

Is this Palisade Bio (PALI) Form 4 filed for one reporting person or a group?

The document indicates that it is a Form filed by one reporting person, specifically director Donald Allen Williams.